非酒精性脂肪性肝炎生物标记市场规模、份额和成长分析（按类型、最终用户和地区）- 产业预测，2025-2032 年

2023 年全球非酒精性脂肪性肝炎生物标记市场规模价值为 10.1 亿美元，预计将从 2024 年的 13 亿美元增长到 2032 年的 97.8 亿美元，预测期内（2025-2032 年）的复合年增长率为 28.7%。

全球非酒精性脂肪性肝炎 (NASH) 生物标记市场预计将出现显着增长，这得益于与肥胖和代谢紊乱相关的慢性肝病 NASH 的盛行率不断上升。发病率的快速增加凸显了对可靠生物标记的需求，以便早期诊断、监测病情进展和评估治疗反应。生物标记对于识别风险群、区分 NASH 与其他肝病以及评估严重程度至关重要。新型非侵入性诊断工具的研究和开发不断进步，进一步增强了这个市场。随着对有效诊断和监控解决方案的需求不断增加，市场相关人员有充足的机会创新并推出满足 NASH 管理关键需求的基于尖端生物标记的产品。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步

非酒精性脂肪性肝炎生物标记市场规模（按类型和复合年增长率）（2025-2032）

• 市场概况
• 肝纤维化生物标记
• 血清生物标记
• 氧化压力生物标誌物
• 细胞凋亡生物标誌物
• 其他的

非酒精性脂肪性肝炎生物标记市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 研究和学术机构
• 诊断中心
• 製药和 CRO
• 医院和诊所
• 其他的

非酒精性脂肪性肝炎生物标记市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Genfit SA（France）
• Gilead Sciences, Inc.（United States）
• Novartis AG（Switzerland）
• Pfizer Inc.（United States）
• Siemens Healthineers AG（Germany）
• Bio-Rad Laboratories, Inc.（United States）
• Abbott Laboratories（United States）
• Prometheus Laboratories Inc.（United States）
• NGM Biopharmaceuticals, Inc.（United States）
• Metabolon, Inc.（United States）
• Perspectum Ltd（United Kingdom）
• Precision Medicine Group, Inc.（United States）
• Grifols, SA（Spain）
• Hologic, Inc.（United States）
• Quest Diagnostics Incorporated（United States）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Biopredictive（France）

结论和建议

Global Non-alcoholic Steatohepatitis Biomarkers Market size was valued at USD 1.01 billion in 2023 and is poised to grow from USD 1.3 billion in 2024 to USD 9.78 billion by 2032, growing at a CAGR of 28.7% during the forecast period (2025-2032).

The Global Non-alcoholic Steatohepatitis (NASH) Biomarkers market is poised for substantial growth, fueled by the rising prevalence of NASH, a chronic liver condition linked to obesity and metabolic disorders. This surge in incidence underscores the need for reliable biomarkers for early diagnosis, monitoring disease progression, and evaluating therapeutic responses. Biomarkers are essential for identifying at-risk individuals, distinguishing NASH from other liver diseases, and assessing severity. The market is further bolstered by advancements in research and the development of novel, non-invasive diagnostic tools. As the demand for effective diagnostic and monitoring solutions grows, market players have ample opportunities to innovate and introduce cutting-edge biomarker-based products, fulfilling the critical needs in NASH management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Alcoholic Steatohepatitis Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Alcoholic Steatohepatitis Biomarkers Market Segmental Analysis

Global Non-alcoholic SteatohepatitisbiomarkersMarket is segmented by Type, End User and region. Based on Type, the market is segmented into Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers and Others. Based on End User, the market is segmented into Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Alcoholic Steatohepatitis Biomarkers Market

A significant driver fueling the global Non-Alcoholic Steatohepatitis (NASH) biomarkers market is the alarming rise in NASH cases globally. This liver condition, characterized by excess fat buildup that leads to inflammation and liver damage, is increasingly prevalent due to factors such as obesity, sedentary lifestyles, and poor dietary choices. Consequently, there is a heightened demand for reliable biomarkers that can facilitate early diagnosis, monitor the progression of the disease, and evaluate treatment efficacy. The escalating awareness surrounding NASH and the necessity for improved diagnostic methods further amplify the need for effective biomarkers in this growing market.

Restraints in the Global Non-Alcoholic Steatohepatitis Biomarkers Market

A notable challenge facing the Global Non-Alcoholic Steatohepatitis (NASH) Biomarkers market is the absence of standardized biomarkers coupled with regulatory hurdles. The intricate processes involved in developing and validating biomarkers for NASH diagnosis and monitoring create significant barriers. The lack of consensus regarding the selection and application of these biomarkers limits their adoption across the industry. Moreover, regulatory bodies enforce strict validation requirements that can be both time-consuming and costly for developers. These complexities hinder the commercialization and acceptance of NASH biomarkers in clinical settings. To overcome these challenges, further research, standardization, and expert regulatory guidance are essential for maximizing the efficacy of NASH biomarkers and enhancing patient care.

Market Trends of the Global Non-Alcoholic Steatohepatitis Biomarkers Market

The global Non-Alcoholic Steatohepatitis (NASH) biomarkers market is witnessing a significant trend towards the adoption of non-invasive diagnostic techniques, reflecting the growing emphasis on patient-centric healthcare. NASH, characterized by complex liver pathology, necessitates early and accurate diagnosis for optimal management. In this landscape, non-invasive biomarkers, including advanced blood-based assays and imaging methods, are emerging as preferred alternatives to traditional liver biopsies, offering enhanced patient comfort, cost-efficiency, and accessibility. This shift not only promises to improve patient outcomes through timely intervention but also facilitates smoother clinical trial processes. As the demand for reliable and convenient diagnostics increases, this trend is poised to accelerate the growth of the global NASH biomarkers market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Non-alcoholic Steatohepatitis Biomarkers Market Size by Type & CAGR (2025-2032)

• Market Overview
• Hepatic Fibrosis Biomarkers
• Serum Biomarkers
• Oxidative Stress Biomarkers
• Apoptosis Biomarkers
• Others

Global Non-alcoholic Steatohepatitis Biomarkers Market Size by End User & CAGR (2025-2032)

• Market Overview
• Research Institutes and Academics
• Diagnostic Centres
• Pharmaceutical Companies and CROs
• Hospitals and Clinics
• Others

Global Non-alcoholic Steatohepatitis Biomarkers Market Size & CAGR (2025-2032)

• North America (Type, End User)
  • US
  • Canada
• Europe (Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Genfit SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prometheus Laboratories Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NGM Biopharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolon, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perspectum Ltd (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision Medicine Group, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biopredictive (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations